Facebook Instagram Twitter RSS Feed PodBean Back to top on side

Disease status in patients with chronic myeloid leukemia is better characterized by BCR-ABL/BCR transcript ratio than by BCR-ABL transcript level, which may suggest a role of normal BCR gene in the disease pathogenesis

In: NEOPLASMA, vol. 52, no. 2
J. Moravcova - J. Regner - D. Mouckova - K. Fiser - V. Zmekova - R. Malacova - K. Michalova - H. Klamova
Detaily:
Rok, strany: 2005, 119 - 125
O článku:
Monitoring of BCR-ABL transcript level is widely used in chronic myeloid leukemia (CML) to follow up response to therapy. In this study we compare abilities of two quantitative RT-PCR assays to characterize the disease status in CML patients: RT-PCR quantifying the BCR-ABL transcript concentration and RT-PCR determining the BCR-ABL/BCR transcript ratio (R). We demonstrate that in non-responders only R, but not BCR-ABL, unambiguously characterizes the state of disease. Moreover, R values >1 found in all poor responders indicate lower BCR expression compared to BCR- ABL in these patients. Our results demonstrate the importance of BCR-ABL/BCR transcript ratio for the disease status and the disease prognosis characterization and suggest a possible role of the normal BCR gene expression in CML pathogenesis.
Ako citovať:
ISO 690:
Moravcova, J., Regner, J., Mouckova, D., Fiser, K., Zmekova, V., Malacova, R., Michalova, K., Klamova, H. 2005. Disease status in patients with chronic myeloid leukemia is better characterized by BCR-ABL/BCR transcript ratio than by BCR-ABL transcript level, which may suggest a role of normal BCR gene in the disease pathogenesis. In NEOPLASMA, vol. 52, no.2, pp. 119-125. 0028-2685.

APA:
Moravcova, J., Regner, J., Mouckova, D., Fiser, K., Zmekova, V., Malacova, R., Michalova, K., Klamova, H. (2005). Disease status in patients with chronic myeloid leukemia is better characterized by BCR-ABL/BCR transcript ratio than by BCR-ABL transcript level, which may suggest a role of normal BCR gene in the disease pathogenesis. NEOPLASMA, 52(2), 119-125. 0028-2685.